Perception, Neuroscience and Behavior Laboratory, Joao Pessoa, Brazil.
Rutgers University Behavioral Health Care, Piscataway, NJ, USA.
Schizophr Res. 2019 Feb;204:162-170. doi: 10.1016/j.schres.2018.09.002. Epub 2018 Sep 7.
Schizophrenia patients (SCZ) demonstrate deficits in many domains of mental functioning, including visual perception. An issue that has been relatively unexplored, in terms of explaining variation in visual function in SCZ, however, is medication use. The present study explored potential medication effects on color vision in SCZ, a process that is strongly linked to dopaminergic function in the retina. SCZ patients who had clear-cut either typical (n = 29) or atypical (n = 29) monotherapy, without any other concurrent medication, and a group of age- and gender-matched healthy controls participated in the study. Color vision was assessed by the Cambridge Colour Test, using the Trivector and Ellipse subtests. The results demonstrated impaired color perception in patients with schizophrenia, especially in those receiving typical antipsychotics, but these deficits were subtle and not generalized to all parameters. Our findings are consistent with the known neurophysiology of the retina and visual pathways, and with the effects of dopamine blocking medications, but the results should be carefully interpreted.
精神分裂症患者（SCZ）在许多心理功能领域表现出缺陷，包括视觉感知。然而，在解释 SCZ 中视觉功能的变化时，一个相对未被探索的问题是药物使用。本研究探讨了精神分裂症患者中潜在的药物对色觉的影响，这一过程与视网膜中的多巴胺能功能密切相关。研究纳入了明确接受典型（n=29）或非典型（n=29）单药治疗、无其他同时使用药物的 SCZ 患者，以及一组年龄和性别匹配的健康对照者。使用 Trivector 和 Ellipse 子测试，通过剑桥颜色测试评估色觉。结果表明精神分裂症患者的色觉感知受损，尤其是接受典型抗精神病药物治疗的患者，但这些缺陷很细微，并不普遍存在于所有参数中。我们的发现与视网膜和视觉通路的已知神经生理学以及多巴胺阻断药物的作用一致，但结果应谨慎解释。
